Multiple Myeloma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
J
A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +140 more
2021-12-02
Dec 2, 2021
J
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Nagoya, Japan
  • +3 more
2021-12-02
Dec 2, 2021
P
P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
Not yet recruiting
  • Multiple Myeloma
  • San Diego, California
  • +2 more
2021-12-01
Dec 1, 2021
J
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
Recruiting
  • Multiple Myeloma
  • San Francisco, California
  • +139 more
2021-12-02
Dec 2, 2021
N
Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Not yet recruiting
  • Multiple Myeloma
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2021-12-02
Dec 2, 2021
J
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +33 more
2021-12-02
Dec 2, 2021
J
Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Birmingham, Alabama
  • +106 more
2021-12-02
Dec 2, 2021
C
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone
  • Atlanta, Georgia
  • +18 more
2021-12-02
Dec 2, 2021
W
Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease
Not yet recruiting
  • Multiple Myeloma
  • Saint Louis, Missouri
    Washington University School of Medicine
2021-12-02
Dec 2, 2021
H
Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant Recurrence
Active, not recruiting
  • Multiple Myeloma
  • Lymphoma
  • Washington, District of Columbia
  • +1 more
2021-12-02
Dec 2, 2021
J
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Birmingham, Alabama
  • +35 more
2021-12-02
Dec 2, 2021
P
MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
Recruiting
  • Multiple Myeloma
  • Elranatamab (PF-06863135)
  • Beverly Hills, California
  • +96 more
2021-12-02
Dec 2, 2021
J
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Recruiting
  • Multiple Myeloma
  • Birmingham, Alabama
  • +28 more
2021-12-02
Dec 2, 2021
J
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Active, not recruiting
  • Multiple Myeloma
  • Beijing, China
  • +43 more
2021-12-02
Dec 2, 2021
J
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
  • Multiple Myeloma
  • JNJ-68284528
  • Phoenix, Arizona
  • +20 more
2021-12-02
Dec 2, 2021
J
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
Active, not recruiting
Has Results
  • Multiple Myeloma
  • Dara SC
  • Dara IV
  • Boston, Massachusetts
  • +146 more
2021-12-02
Dec 2, 2021
H
Multiple Myeloma Molecular Monitoring Study
Recruiting
  • Multiple Myeloma
    • Calgary, Alberta, Canada
    • +12 more
    2021-12-02
    Dec 2, 2021
    J
    A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
    Active, not recruiting
    • Multiple Myeloma
    • Beijing, China
    • +26 more
    2021-12-02
    Dec 2, 2021
    J
    Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab
    Recruiting
    • Multiple Myeloma
    • Carfilzomib 20 mg/m^2
    • +4 more
    • Gilbert, Arizona
    • +113 more
    2021-12-02
    Dec 2, 2021
    J
    A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
    Recruiting
    • Multiple Myeloma
    • Duarte, California
    • +24 more
    2021-12-02
    Dec 2, 2021
    J
    A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma
    Active, not recruiting
    • Multiple Myeloma
    • Beijing, China
    • +4 more
    2021-12-02
    Dec 2, 2021
    J
    A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
    Active, not recruiting
    • Multiple Myeloma
    • No intervention
    • Tucson, Arizona
    • +85 more
    2021-12-02
    Dec 2, 2021
    S
    Post-Op Pain Control for Prophylactic Intramedullary Nailing.
    Recruiting
    • Bone Metastases
    • +4 more
    • Saint Louis, Missouri
      Saint Louis University
    2021-12-02
    Dec 2, 2021
    J
    A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
    Active, not recruiting
    • Multiple Myeloma
    • Birmingham, Alabama
    • +87 more
    2021-12-02
    Dec 2, 2021
    J
    A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
    Active, not recruiting
    • Multiple Myeloma
    • Whittier, California
    • +113 more
    2021-12-02
    Dec 2, 2021